Charles River Laboratories (CRL) Tops Q1 EPS by 12c, Raises FY EPS Guidance
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $1.38, $0.12 better than the analyst estimate of $1.26. Revenue for the quarter came in at $494.4 million versus the consensus estimate of $480.75 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.77-$5.92, versus the consensus of $5.76.
| 2018 GUIDANCE INCLUDING MPI RESEARCH(from continuing operations) | REVISED | PRIOR | |||||
| Revenue growth, reported | 18% - 20% | 16% - 18% | |||||
| Less: Contribution from acquisitions (1) | (9.5% - 10.5%) | (9.5% - 10.5%) | |||||
| Less: Favorable impact of foreign exchange | (~3%) | (~1%) | |||||
| Revenue growth, organic (2) | 5.7% - 6.7% | 5.7% - 6.7% | |||||
| GAAP EPS estimate | $4.22-$4.37 | --- | |||||
| Amortization of intangible assets (3) | $1.00-$1.10 | --- | |||||
| Charges related to global efficiency initiatives (4) | $0.09 | --- | |||||
| Acquisition-related adjustments (5) | $0.41 | --- | |||||
| Non-GAAP EPS estimate | $5.77 - $5.92 | $5.67 - $5.82 |
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here
.